Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Dec 19;28(1):20.
doi: 10.1007/s10151-023-02878-z.

Microbiome-preserving antibiotics for the treatment of Clostridioides difficile infection: a systematic review and meta-analysis

A M Kravets  1 , R Hanneke  2 , R L Nelson  3
Affiliations
Meta-Analysis

Microbiome-preserving antibiotics for the treatment of Clostridioides difficile infection: a systematic review and meta-analysis

A M Kravets et al. Tech Coloproctol. .

Abstract

Background: Newer antibiotics that specifically target Clostridioides difficile while preserving the host microbiome have emerged to treat C. difficile infection (CDI): cadazolid, fidaxomicin, ridinilazole, and surotomycin. The aim of the present study was to perform a systematic review and meta-analysis of efficacy for each antibiotic.

Methods: Only randomized clinical trials of patients being treated for Clostridioides disease infection were included. Studies were sought in MEDLINE, EMBASE, the Cochrane Register of Controlled Trials, ClinicalTrials.gov, and the World Health Organization clinical trials register portal (up to December 9, 2022). Sustained clinical cure was the outcome of treatment comparison, defined as the resolution of diarrhea without recurrence. Vancomycin was the standard treatment comparator. Meta-analysis was performed for each antibiotic. The overall certainty of evidence was assessed using Grading of Recommendations Assessment, Development, and Evaluation (GRADE)-classified as either high, moderate, low, or very low.

Results: Fourteen eligible studies were included in the meta-analysis with 4837 patients from 773 sites. Cadazolid did not increase sustained clinical cure relative to vancomycin (risk ratio (RR) 1.04, 95% confidence intervals (CI) 0.96-1.13; moderate-certainty evidence). Fidaxomicin demonstrated a significant increase (RR 1.14, 95% CI 1.07-1.21; low-certainty evidence). In one phase 2 study, ridinilazole demonstrated a significant increase in sustained clinical cure (RR 1.71, 95% CI 1.01-2.91; very low-quality evidence). Surotomycin did not show significant improvement (RR 1.05, 95% CI 0.96-1.14; moderate-certainty evidence).

Conclusions: Fidaxomicin (in seven studies) demonstrated significant improvement in achieving sustained clinical cure. A limitation of this study may that more studies are needed to compare fidaxomicin with other antibiotics.

Keywords: Clostridioides difficile infection (CDI); Gut microbiome; New antibiotic therapy for CDI; Sustained cure of CDI.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Guh AY, Mu Y, Winston LG et al (2020) Trends in U.S. burden of clostridioides difficile infection and outcomes. N Engl J Med 382(14):1320–1330. https://doi.org/10.1056/NEJMoa1910215 - DOI - PubMed - PMC
    1. Centers for Disease Control and Prevention, National Center for Health Statistics. Underlying Cause of Death 1999–2020 on CDC WONDER Online Database, released in 2021. Data are from the Multiple Cause of Death Files, 1999–2020, as compiled from data provided by the 57 vital statistics jurisdictions through the vital statistics cooperative program. at http://wonder.cdc.gov/ucd-icd10.html . Accessed 1 Mar 2022
    1. Goyal H, Perisetti A, Rehman MR, Singla U (2018) New and emerging therapies in treatment of Clostridium difficile infection. Eur J Gastroenterol Hepatol 30(6):589–597. https://doi.org/10.1097/MEG.0000000000001103 - DOI - PubMed
    1. Petrosillo N, Granata G, Cataldo MA (2018) Novel antimicrobials for the treatment of Clostridium difficile infection. Front Med 5:96. https://doi.org/10.3389/fmed.2018.00096 - DOI
    1. Ooijevaar RE, van Beurden YH, Terveer EM et al (2018) Update of treatment algorithms for Clostridium difficile infection. Clin Microbiol Infect 24(5):452–462. https://doi.org/10.1016/j.cmi.2017.12.022 - DOI - PubMed
Excluded studies
    1. Lee CH, Patino H, Stevens C et al (2016) Surotomycin versus vancomycin for Clostridium difficile infection: phase 2, randomized, controlled, double-blind, non-inferiority, multicentre trial. J Antimicrob Chemother 71(10):2964–2971. https://doi.org/10.1093/jac/dkw246 - DOI - PubMed
    1. Louie TJ, Miller MA, Mullane KM et al (2011) Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 364(5):422–431. https://doi.org/10.1056/NEJMoa0910812 - DOI - PubMed
    1. Cornely OA, Crook DW, Esposito R et al (2012) Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 12(4):281–289. https://doi.org/10.1016/S1473-3099(11)70374-7 - DOI - PubMed
    1. Louie T, Nord CE, Talbot GH et al (2015) Multicenter, double-blind, randomized, phase 2 Study evaluating the novel antibiotic cadazolid in patients with Clostridium difficile infection. Antimicrob Agents Chemother 59(10):6266–6273. https://doi.org/10.1128/AAC.00504-15 - DOI - PubMed - PMC
    1. Boix V, Fedorak RN, Mullane KM et al (2017) Primary outcomes from a phase 3, randomized, double-blind, active-controlled trial of surotomycin in subjects with Clostridium difficile infection. Open Forum Infect Dis 4(1):ofw275. https://doi.org/10.1093/ofid/ofw275 - DOI - PubMed - PMC
Included studies
    1. Dubberke ER, Gerding DN, Kelly CP et al (2020) Efficacy of bezlotoxumab in participants receiving metronidazole, vancomycin, or fidaxomicin for treatment of Clostridioides (Clostridium) difficile infection. Open Forum Infect Dis 7(6):ofaa157. https://doi.org/10.1093/ofid/ofaa157 - DOI - PubMed - PMC
    1. Gawronska A, Banasiuk M, Lachowicz D, Pituch H, Albrecht P, Banaszkiewicz A (2017) Metronidazole or rifaximin for treatment of Clostridium difficile in pediatric patients with inflammatory bowel disease: a randomized clinical trial. Inflamm Bowel Dis 23(12):2209–2214. https://doi.org/10.1097/MIB.0000000000001249 - DOI - PubMed
    1. Fabre V, Dzintars K, Avdic E, Cosgrove SE (2018) Role of metronidazole in mild Clostridium difficile infections. Clin Infect Dis 67(12):1956–1958. https://doi.org/10.1093/cid/ciy474 - DOI - PubMed
    1. Appaneal HJ, Caffrey AR, LaPlante KL (2019) What is the role for metronidazole in the treatment of Clostridium difficile infection? Results from a national cohort study of veterans with initial mild disease. Clin Infect Dis 69(8):1288–1295. https://doi.org/10.1093/cid/ciy1077 - DOI - PubMed
    1. Frelick M. C Diff recurrence drops with highly targeted ridinilazole. https://www.medscape.com/viewarticle/98297
Further citations
    1. https://en.wikipedia.org/wiki/Surotomycin
    1. Nelson RL, Suda KJ, Evans CT (2017) Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults. Cochrane Database Syst Rev 3(3):CD004610. https://doi.org/10.1002/14651858.CD004610 - DOI - PubMed
    1. Zhang VRY, Woo ASJ, Scaduto C et al (2021) Systematic review on the definition and predictors of severe Clostridiodes difficile infection. J Gastroenterol Hepatol 36(1):89–104. https://doi.org/10.1111/jgh.15102 - DOI - PubMed
    1. (2021) Treatment of Clostridioides difficile infection. Med Lett Drugs Ther 63(1632):137–141
    1. Kim J, Kim J, Kim B, Pai H (2022) Which is the preferred regimen for non-severe Clostridioides difficile infection in Korea, vancomycin or metronidazole? Infect Chemother 54(2):213–219. https://doi.org/10.3947/ic.2022.0027 - DOI - PubMed - PMC

MeSH terms

LinkOut - more resources